Key result
Dual antiplatelet therapy following percutaneous coronary intervention is shifting toward shorter durations and individualized regimens to balance bleeding and ischemic risks.
Why the study?
Recent trials show reduced bleeding with shorter DAPT durations not yet reflected in guidelines, alongside an ongoing shift toward individualized antiplatelet regimens.
Answers are grounded in this paper and cite their sources.
The review highlights a paradigm shift towards shorter and more individualized DAPT regimens post-PCI to minimize bleeding risks while maintaining ischemic protection.
A C TDual antiplatelet therapy (DAPT) has been paramount in preventing thrombosis following percutaneous coronary intervention for nearly 3 decades.However, over the years, DAPT has seen significant changes in the agents utilized and duration of therapy as trials have raced to keep up with advancements made in stent technology and our understanding of bleeding and ischemic risk.Recently, there have been a number of trials demonstrating significant reductions in bleeding events with shorter DAPT durations, which are not yet reflected in practice guidelines.Further, there has been a shift toward more individualized antiplatelet regimens to meet patient-specific risk profiles.This review provides a comprehensive summary of the major trials that have informed current DAPT strategies, puts into context recent trials driving a shift toward more tailored antiplatelet regimens, and highlights gaps in knowledge that remain and the ongoing trials designed to address them. Goals of antiplatelet therapyThe utility of antiplatelet agents in acute coronary syndromes (ACS) was first described by Paul Gibson in his letter "Salicylic acid for coronary thrombosis?" from 1948. 1 As plaque rupture and subsequent platelet aggregation were better understood as the pathophysiologic mechanisms behind ACS, aspirin became mainstay therapy, with large trials subsequently confirming its therapeutic benefit. 2 With the placement of the first coronary stents in the late 1980s, a new concern for stent thrombosis and its 5% to 45% mortality rate arose. 3Anticoagulation was first attempted to prevent this devastating complication with regimens comprising aspirin, dipyridamole, heparin, and eventually warfarin for 1 to 3 months after stent placement. 4In 1995, Colombo et al 5 reported an initial experience of 359 patients who underwent Palmaz-Schatz stent placement with intravascular ultrasound optimization using only ticlopidine and/or aspirin antiplatelet therapy, pioneering both the use of intravascular ultrasound for stent dilation as well as antiplatelet therapy without anticoagulation after stent placement.Subsequently, ticlopidine, the first P2Y purinoceptor 12 inhibitors (P2Y 12 i), demonstrated superior outcomes in the ISAR trial (1996) by reducing the rates of both stent thrombosis and hemorrhagic complications in comparison to anticoagulation, thereby ushering in the era of dual antiplatelet therapy (DAPT) with aspirin and a P2Y 12 i. 6Ticlopidine, however, was poorly tolerated and had multiple undesirable gastrointestinal and hematologic side effects leading to its replacement with clopidogrel and then additional and more potent P2Y 12 i, prasugrel, and ticagrelor. 7Since then, there has been an intense devotion to the refinement of antiplatelet therapies.Early post-percutaneous coronary intervention (PCI) DAPT strategies focused on minimizing ischemic and thrombotic complications through DAPT intensification, following an increased risk of early and late stent thrombosis with first-generation drug-eluting stents (DESs). 8There subsequently has been a shift toward shorter and/or less intense DAPT therapy as advancements in DES technology have minimized thrombotic complications, and awareness
No takes yet. Share an insight, caveat, or question.
Thomas et al. (2023) conducted a review in Percutaneous coronary intervention. Dual antiplatelet therapy (DAPT) was evaluated. Dual antiplatelet therapy following percutaneous coronary intervention is shifting toward shorter durations and individualized regimens to balance bleeding and ischemic risks.
Synapse has enriched 10 related papers. Consider them for comparative context: